Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 2
---
-100 reverse stock split effective January 8, 2025
and 1-for-20 reverse stock split effective June 13, 2025

1

CERO THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS

(Unaudited)

    For the  Three Months Ended September 30, 2025  
    For the  Three Months Ended September 30,  2024  
    For the Nine Months Ended September 30, 2025  
    For the Period from February 14, 2024 through September 30,  2024  
    For the Period from January 1, 2024  through February 13, 2024 

    (Successor)  
    (Successor)  
    (Successor)  
    (Successor)  
    (Predecessor) 
  
    Operating expenses: 

    Research and development 
    $2,386,244  
    $1,774,210  
    $8,048,034  
    $5,392,569  
    $764,192 
  
    General and administrative 
     1,976,335  
     2,628,028  
     5,988,867  
     7,812,843  
     132,941 
  
    Total operating expenses 
     4,362,579  
     4,402,238  
     14,036,901  
     13,205,412  
     897,133 
  
    Loss from operations 
     (4,362,579) 
     (4,402,238) 
     (14,036,901) 
     (13,205,412) 
     (897,133)

    Other income (expenses): 

    Gain from settlement of liabilities with vendors 
     -  
     -  
     -  
     589,223  
     - 
  
    Other income (expenses) 
     248  
     (147) 
     248  
     (630,922) 
     - 
  
    Change in fair value of earnout and derivative liabilities 
     -  
     170,000  
     -  
     4,870,